8-K
filed June 7, 2022, 7:59 PM ET
ticker ERNA
CIK 0000748592
leadership
confidence high
sentiment neutral
materiality 0.65
Brooklyn ImmunoTherapeutics replaces four directors; appoints Angel, Fiore, Wexler, Singer
Ernexa Therapeutics Inc.
- Four directors (Langer, Mohr, Enright, Redman) resigned effective June 5, 2022; no disagreement cited.
- Board size reduced from six to five; then appointed four new directors to fill vacancies.
- Appointees include Matthew Angel (interim CEO), Gregory Fiore (CEO of Exacis), William Wexler (restructuring expert), Nicholas Singer (founder of Purchase Capital).
- Wexler and Singer deemed independent; Singer qualifies as audit committee financial expert.
- No material transactions with new directors except prior rights offering participation by Singer ($1.29M) and Angel's prior appointment.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Gregory Fiore was appointed as Director at Ernexa Therapeutics Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Erich Mohr resigned as Director at Ernexa Therapeutics Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
William Wexler was appointed as Director at Ernexa Therapeutics Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Dennis Langer resigned as Director at Ernexa Therapeutics Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Matthew Angel was appointed as Director at Ernexa Therapeutics Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Nicholas Singer was appointed as Director at Ernexa Therapeutics Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
On June 5, 2022, the Board appointed each of Dr. Angel, Dr. Fiore, Mr. Wexler and Mr. Singer as directors, with effect immediately following the effectiveness of the resignations of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman on June 5, 2022 to fill the existing vacancies on the Board created thereby.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Erin Enright resigned as Director at Ernexa Therapeutics Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Heather Redman resigned as Director at Ernexa Therapeutics Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 5, 2022 each of Dr. Langer, Dr. Mohr, Ms. Enright and Ms. Redman resigned from the Board, with such resignations effective immediately following Board’s action to decrease the size of the Board from six to five directors and appoint each of Dr. Matthew Angel, Dr. Gregory Fiore, Mr. William Wexler and Mr. Nicholas Singer to the Board, as described below.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.